These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 27860547)

  • 1. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suvorexant (Belsomra) for insomnia.
    Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
    Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
    BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orexin OX
    Jacobson LH; Chen S; Mir S; Hoyer D
    Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
    Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
    J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription Drugs Used in Insomnia.
    Dujardin S; Pijpers A; Pevernagie D
    Sleep Med Clin; 2020 Jun; 15(2):133-145. PubMed ID: 32386689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suvorexant: something new for sleep?
    Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
    Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
    Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
    Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of orexin receptor antagonism on human sleep architecture: A systematic review.
    Clark JW; Brian ML; Drummond SPA; Hoyer D; Jacobson LH
    Sleep Med Rev; 2020 Oct; 53():101332. PubMed ID: 32505969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.
    Yin J; Mobarec JC; Kolb P; Rosenbaum DM
    Nature; 2015 Mar; 519(7542):247-50. PubMed ID: 25533960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward the Mysteries of Sleep.
    Yanagisawa M
    Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.